Dhaval Sangoi
Fund manager Dhaval Sangoi: portfolio changes across the 1 scheme AMFI's scheme summary documents name them on, Oct 2026, by share count.
Equity.
1 with AMFI average AUM, July - September 2026; each scheme in full, not split between co-managers. Source: AMFI.
On a scheme named on today, as the fund house files it. Source: AMFI SSD.
People named on at least one of the same schemes.
| Scheme | Fund house | Category | AUM | Role, as filed | Since, as filed | As of |
|---|---|---|---|---|---|---|
| LIC MF Healthcare Fund | LIC Mutual Fund | Equity Scheme - Sectoral/ Thematic | ₹99.4 cr | — | — | 2 Nov 2026 |
From each scheme's summary document on AMFI's site (scheme details), as it stood on the date shown. How to read
Named on the same scheme's summary document; the number is how many schemes they share. Source: AMFI SSD.
- ₹8.4 cr
- ₹6.8 cr
- ₹5.9 cr
- ₹5.8 cr
- ₹5.6 cr
- ₹5.2 cr
- ₹4.5 cr
- ₹4.0 cr
- ₹3.7 cr
- ₹3.6 cr
| Ticker | Company | Value | % of equity held | Schemes holding |
|---|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries Limited | ₹8.4 cr | 9.0 % | 1 |
| DIVISLAB | Divi's Laboratories Limited | ₹6.8 cr | 7.4 % | 1 |
| APOLLOHOSP | Apollo Hospitals Enterprise Limited | ₹5.9 cr | 6.4 % | 1 |
| TORNTPHARM | Torrent Pharmaceuticals Limited | ₹5.8 cr | 6.2 % | 1 |
| NEULANDLAB | Neuland Laboratories Limited | ₹5.6 cr | 6.1 % | 1 |
| AUROPHARMA | Aurobindo Pharma Limited | ₹5.2 cr | 5.6 % | 1 |
| ASTERDM | Aster DM Quality Care Limited | ₹4.5 cr | 4.8 % | 1 |
| NEPHROPLUS | Nephrocare Health Services Ltd. | ₹4.0 cr | 4.3 % | 1 |
| FORTIS | Fortis Healthcare Limited | ₹3.7 cr | 4.0 % | 1 |
| METROPOLIS | Metropolis Healthcare Limited | ₹3.6 cr | 3.9 % | 1 |
| GLAND | Gland Pharma Limited | ₹3.4 cr | 3.7 % | 1 |
| ZYDUSLIFE | Zydus Lifesciences Limited | ₹3.1 cr | 3.4 % | 1 |
| COHANCE | Cohance Lifesciences Limited | ₹2.9 cr | 3.2 % | 1 |
| PPLPHARMA | Piramal Pharma Limited | ₹2.9 cr | 3.1 % | 1 |
| MAXHEALTH | Max Healthcare Institute Limited | ₹2.8 cr | 3.0 % | 1 |
The 15 largest holdings by market value, summed over the schemes this manager is named on today.
1 scheme has no filed start date, so no return is shown
Each scheme's direct-growth return over the dates filed for this manager, next to its category's average. Returns and averages are computed by this site from AMFI NAVs; they are not the fund house's figures. Past performance may not be sustained in future.
| Month | Schemes with a change | Stocks added | Stocks cut | Bought | Sold | Net |
|---|---|---|---|---|---|---|
| Oct 2026 | 1 | 6 | 9 | ₹8.3 cr | ₹12.6 cr | −₹4.4 cr |
| Sep 2026 | 1 | 6 | 9 | ₹6.3 cr | ₹5.9 cr | +₹0.37 cr |
| Aug 2026 | 1 | 5 | 1 | ₹3.4 cr | ₹1.3 cr | +₹2.1 cr |
| Jul 2026 | 1 | 5 | 2 | ₹6.8 cr | ₹4.2 cr | +₹2.6 cr |
| Jun 2026 | 1 | 1 | 0 | ₹1.8 cr | ₹0.00 cr | +₹1.8 cr |
| May 2026 | 1 | 7 | 8 | ₹14.1 cr | ₹16.2 cr | −₹2.2 cr |
| Feb 2026 | 1 | 7 | 1 | ₹1.5 cr | ₹1.3 cr | +₹0.14 cr |
| Jan 2026 | 1 | 4 | 2 | ₹0.49 cr | ₹1.9 cr | −₹1.4 cr |
| Dec 2025 | 1 | 4 | 4 | ₹0.65 cr | ₹1.7 cr | −₹1.0 cr |
| Nov 2025 | 1 | 2 | 4 | ₹0.73 cr | ₹1.5 cr | −₹0.81 cr |
Across the schemes this manager is named on today, by share count.
Changes seen in AMFI's documents
since 29 Sep 2026
Changes on this manager's schemes, by the date AMFI's document first showed them.
Added 6
6 stocks · largest 6 by value
| Stock | Schemes | Implied change, share count × price | Price 30 Oct 2026, 12‑month change |
|---|---|---|---|
| YATHARTH | 1 | +₹2.1 cr | ₹926.90 ▲ +16.4% |
| RAINBOW | 1 | +₹2.0 cr | ₹1,218.70 ▼ −11.0% |
| FLUOROCHEM | 1 | +₹1.5 cr | ₹4,248.20 ▲ +13.5% |
| PPLPHARMA | 1 | +₹1.2 cr | ₹238.91 ▲ +19.7% |
| NEPHROPLUS | 1 | +₹1.2 cr | ₹614.55 ▲ +31.1% |
| METROPOLIS | 1 | +₹0.25 cr | ₹545.65 ▲ +10.8% |
Cut 9
9 stocks · largest 9 by value
| Stock | Schemes | Implied change, share count × price | Price 30 Oct 2026, 12‑month change |
|---|---|---|---|
| DIVISLAB | 1 | −₹2.6 cr | ₹9,780.00 ▲ +45.1% |
| NAVINFLUOR | 1 | −₹2.6 cr | ₹8,680.00 ▲ +52.6% |
| MEDANTA | 1 | −₹2.2 cr | ₹1,270.30 ▼ −3.1% |
| ZYDUSLIFE | 1 | −₹2.2 cr | ₹1,245.50 ▲ +27.8% |
| ARTEMISMED | 1 | −₹1.3 cr | ₹293.20 ▲ +18.4% |
| SUNPHARMA | 1 | −₹0.97 cr | ₹1,777.70 ▲ +5.1% |
| MANKIND | 1 | −₹0.33 cr | ₹2,492.80 ▲ +4.6% |
| GLENMARK | 1 | −₹0.23 cr | ₹2,298.70 ▲ +21.5% |
| IPCALAB | 1 | −₹0.19 cr | ₹1,927.80 ▲ +51.7% |
Each scheme's change in shares at its month-end price, summed over this manager's schemes, Oct 2026.
Questions about Dhaval Sangoi
from the figures on this pageWhat stocks are in Dhaval Sangoi's portfolio?
The 1 scheme Dhaval Sangoi manages held 27 stocks worth ₹92.9 cr at Oct 2026 end. Largest: Sun Pharmaceutical Industries 9.0 %, Divi's Laboratories 7.4 %, Apollo Hospitals Enterprise 6.4 %, Torrent Pharmaceuticals 6.2 %, Neuland Laboratories 6.1 %. Sun Pharmaceutical Industries mutual fund holdings · Divi's Laboratories mutual fund holdings · Apollo Hospitals Enterprise mutual fund holdings
Which stocks did Dhaval Sangoi buy and sell in Oct 2026?
In Oct 2026, Dhaval Sangoi's schemes added to 6 stocks, largest Yatharth Hospital & Trauma Care Serv Ltd (YATHARTH), Rainbow Childrens Medicare (RAINBOW), Gujarat Fluorochemicals (FLUOROCHEM); cut 9, largest Divi's Laboratories (DIVISLAB), Navin Fluorine International (NAVINFLUOR), Global Health (MEDANTA), by value at month-end prices.
Which mutual fund schemes does Dhaval Sangoi manage?
AMFI's scheme summary documents name Dhaval Sangoi (LIC Mutual Fund) for 1 scheme: LIC MF Healthcare Fund. LIC MF Healthcare Fund portfolio